Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020
February 06 2020 - 7:00AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development, and commercialization of
novel therapies for the treatment of cancer, today announced that
it will release fourth quarter and full year 2019 financial results
on Thursday, February 27, 2020, before the market opens, and host a
conference call and live audio webcast 8:00am Eastern Time to
discuss the financial results and provide a business update.
To participate in the call, dial 877-407-0784
(domestic) or 201-689-8560 (international) fifteen minutes before
the conference call begins and reference the conference passcode
13698005. The live conference call and replay can also be accessed
via audio webcast at the Investor Relations section of the
Company’s website, located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized around
three platforms, including an Oncology Innovation Platform, a
Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices in Buffalo and Clarence, New York;
Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong;
Taipei, Taiwan; multiple locations in Chongqing, China; Manchester,
UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more
information, please visit www.athenex.com.
CONTACTSInvestor Relations:Tim
McCarthyManaging Director, LifeSci Advisors, LLCDirect:
212-915-2564
Athenex, Inc.:Randoll SzeChief Financial
OfficerEmail: RandollSze@athenex.com
Jacqueline LiCorporate Development and Investor
RelationsEmail: JacquelineLi@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024